MYC and lymphoma: Carfilzomib was also found to work synergistically with phosophoinositidine 3-kinase (PI3K) inhibitor TGR-1202 to prevent c-Myc translation and c-Myc dependent transcription, contributing to lymphoma and leukemia cell death [183].